Following the SUSTAIN-6 findings, the Ozempic Summary of Product Characteristics (SmPC) and specialist ophthalmology guidance emphasise the importance of: Assessing retinopathy status before initiating semaglutide Ensuring patients are up-to-date with diabetic eye screening Considering the rate of anticipated glycaemic improvement More frequent monitoring in high-risk individuals The consensus among UK diabetes specialists is that semaglutide remains an important therapeutic option, but prescribers should exercise particular caution in patients with established retinopathy and poor baseline glycaemic control
The SmPC for Mounjaro notes that slower dose titration or temporary pauses in dose escalation may help mitigate gastrointestinal adverse effects
Very few studies have investigated semaglutide interest using Google Trends data [42, 72] and these did not employ appropriate analyses for autocorrelated time series data
CHRISTINE BAINES Always great advice
Symptoms of Mast Cell Activation Syndrome: Symptoms of mast cell activation syndrome include:[ref] People with MCAS will usually have some, but not all , of the above symptoms
The criteria for participation were: amenorrhea for 6+ months and not pregnant normal development no markers of metabolic disease weight stable for the last 12 months (noted that subjects were 5-9% below ideal weight) normal adrenal and thyroid hormones Patients were divided into two groups 10 patients with LH less than 3 IU/mL (average of 0.9 +/- 0.1) and 10 with LH greater than 3 IU/mL (average of 7.1 +/- 1.5)